Information about Liraglutide
Liraglutide is a recombinant DNA produced polypeptide analogue of human glucagon-like peptide-1 (GLP-1) which is used in combination with diet and exercise in the therapy of type 2 diabetes, either alone or in combination with other antidiabetic agents.
Liver safety of Liraglutide
There have been no published reports of hepatotoxicity attributed to liraglutide therapy.
Mechanism of action of Liraglutide
Liraglutide (lir" a gloo' tide) is a glucagon-like peptide-1 (GLP-1) analogue that acts like the native gastrointestinal hormone (incretin) to increase insulin secretion. Liraglutide reproduces the activity of GLP-1, binding to specific receptors on pancreatic beta cells and increasing insulin secretion, which can lead to improvement of glycemic control in patients with type 2 diabetes.
Recombinant DNA produced
Liraglutide is a recombinant DNA produced polypeptide that shares 97% homology to endogenous human GLP-1(7-37), which represents 20% of circulating GLP-1 activity in serum. Unlike GPL-1(7-37), however, liraglutide is resistant to DPP-4 degradation and thus has a prolonged duration of activity. Liraglutide, like other GLP-1 analogues, must be given parenterally.
FDA approval information for Liraglutide
Liraglutide was approved for use in the United States in 2010 and current indications are for management of glycemic control in adults with type 2 diabetes in combination with diet and exercise, with or without other oral hypoglycemic agents.
Brand name for Liraglutide
Dosage and administration for Liraglutide
Side effects of Liraglutide
Novo Nordisk has made direct-to-consumer advertising of liraglutide in Sweden (May 2011), through a 6-page supplement in the free newspaper Metro. Although the name of the drug was not explicitly mentioned (this is illegal in the European Union), it could easily be identified through supplied information on dosage and pharmacodynamics.
- Alpha-Glucosidase Inhibitors
- Incretin-Based Drugs
- Metiglinide Analogues
- Sodium Glucose Cotransporter-2 (SGLT-2) Inhibitors